Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00486369
Status:
COMPLETED
Last Update Posted:
2007-06-14
First Post:
2007-06-13
Brief Title:
SMC021A - Absorption Efficacy and Tolerance in Patients With Osteoarthritis A Placebo-Controlled 14-Days Study
Sponsor:
Nordic Bioscience AS
Organization:
Nordic Bioscience AS
Study Overview
Official Title:
SMC021A - Absorption Efficacy and Tolerance in Patients With Osteoarthritis A Placebo-Controlled 14-Days Study
Status:
COMPLETED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to expose patients with OA to calcitonin and to determine plasma calcitonin levels after administration of 06 mg and 08 mg oral calcitonin Also the purpose is to assess the effect of different doses of oral calcitonin 06 mg and 08 mg oral compared to placebo on serum CTX-I and CTX-II Finally to assess the tolerance profile of different dosesformulations of oral calcitonin compared to placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None